Status:
COMPLETED
Platelet Rich Plasma and Diabetic Foot Ulcer
Lead Sponsor:
Zagazig University
Conditions:
Platelet Rich Plasma
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
In chronic diabetic foot ulcer, if the conventional dressing fails, new therapeutic options such as recombinant human growth factors and bioengineered skin substitutes may be beneficial, but the cost ...
Detailed Description
The term "chronic wound" was first used in literature in the 1950s to refer to wounds that were difficult to heal or did not follow a normal healing process. However, the term has met criticism for it...
Eligibility Criteria
Inclusion
- \- Patients with chronic diabetic foot ulcers more than 1 cm in diameter that failed to heal in three months after wound debridement and dressing by a surgeon.
Exclusion
- Patients with evident local infection or gangrene (no redness, no hotness, no purulent discharge, no osteomyelitis in X-ray with a negative probe to bone test, and negative C-reactive protein).
- Patients with end-stage organ failure, hepatic, or renal failure.
- Patients on anticoagulants.
- Patients on antiplatelet agents.
- Patients with thrombocytopenia.
- Patients on steroid therapy.
- Ulcers less than 1cm or greater than 8 cm in diameter.
- Deep ulcers more than 2 cm in depth.
- Patients with lower limb ischemia (acute or chronic). Limb ischemia was excluded by the detection of the distal limb pulsations with ankle-brachial index\>0.9.
Key Trial Info
Start Date :
January 16 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 20 2021
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT04750837
Start Date
January 16 2020
End Date
January 20 2021
Last Update
February 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zagazig University Faculty of Human Medicine
Zagazig, Sharqia Province, Egypt, 44519